Therefore, targeting CXCR2 signaling might be a novel targeted therapy in TKI-resistant CML patients through the suppression of AKT/mTOR and c-MYC [84]. This evidence concerns the gene AKT1 and chronic myelogenous leukemia, BCR-ABL1 positive.